Current Drug Scheduling Reviews Reported by DEA
Sandy Ghozland, Srihari R. Tella, Michelle D. Walker, Susan Carr, Christine A. Sannerud
The FASEB Journal April 1, 2009 DOI: 10.1096/fasebj.23.1_supplement.588.1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Drug control Hallucinogen Pharmacology Controlled substance |
| Key findings | The DEA is actively reviewing numerous substances, including hallucinogens and other drugs, for possible control under the Controlled Substances Act based on abuse potential. |
Abstract
Pursuant to the Controlled Substances Act (CSA), DEA collects and reviews scientific, medical and other data for substances with abuse potential for possible placement under the CSA. The administrative process for scheduling is ongoing for indiplon, carisoprodol, dextromethorphan, salvinorin A and several petitions requesting a change in the control status of nabilone, methylphenidate product, removal of marijuana and tetrahydrocannabinols (THCs) from schedule I, control of tramadol, control of several substances as schedule III anabolic steroids, decontrol of sibutramine. Numerous hallucinogenic substances have become popular among drug abusers in recent years. DEA is currently reviewing the data for several hallucinogens including 5‐MeO‐DMT, 5‐MeO‐AMT, 5‐MeO‐DET, 5‐MeO‐MIPT, DIPT, 4‐OH‐DIPT, 2C‐I, 2C‐T‐2, and Bromo‐dragonfly for possible control under the CSA. Chemical synthesis/pharmacological studies for DOC, 2C‐C, 2C‐D, and 2C‐E are ongoing to determine if they meet the requirements for possible control under the CSA. To comply with the 1971 Convention on Psychotropic Substances, DEA is reviewing zipeprol, amineptine, mesocarb, 4‐methylthioamphetamine (4‐MTA) and brotizolam, which are not currently controlled or marketed in the United States, for control under the CSA.